MedTrace Logo

HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment

NCT04613297 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2022-08-03

No results posted yet for this study

Summary

The aim of the research is to study the immune checkpoint linked to the HLA-G molecule in the dysregulation of the control of COVID-19 infection.

Conditions

  • Covid19

Interventions

OTHER

Baseline and during hospitalization blood samples

Blood sample will be performed at the inclusion visit for all patient and for the hospitalized COVID-19 infected patients, extra-blood samples will be performed : * at day 3 * day 5 and * In case of aggravation * At the discharge from hospital

OTHER

Baseline blood sample

Blood sample will be performed at the inclusion visit only

Sponsors & Collaborators

  • Hopital Foch

    lead OTHER

Principal Investigators

  • Olivier BRUGIERE, PhD · Hopital Foch

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-19
Primary Completion
2022-07-19
Completion
2022-07-19

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04613297 on ClinicalTrials.gov